Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Medical Oncology · Hormone Receptor-Positive/HER2-Negative Breast Cancer

Treating HR-Positive/HER2-Negative Breast Cancer

At a Glance

For HR-positive/HER2-negative breast cancer, treatment usually combines surgery and radiation for early disease with long-term hormone-blocking therapy. Higher-risk or metastatic cancer may also need targeted medicines chosen by tumor biomarkers.

The treatment for Hormone Receptor-Positive (HR+), HER2-negative breast cancer combines local therapies, such as surgery and radiation, with a systemic foundation of endocrine therapy [1]. Because these cancer cells have “docking stations” for estrogen or progesterone, the primary goal of treatment is to block these hormones or stop the body from producing them entirely [2].

Early-Stage Treatment: The Foundation

For cancer that hasn’t spread to distant parts of the body, treatment focuses on reducing the risk of the cancer coming back. Local treatments like breast surgery (lumpectomy or mastectomy) and radiation are critical first steps for most patients to remove the tumor. Once local treatment is complete, systemic treatment begins.

  • Endocrine Therapy: This is the “backbone” of your systemic care, commonly given for 5 to 10 years, with the exact duration individualized based on your recurrence risk [1]. Managing its side effects is crucial: hot flashes, joint pain, and vaginal dryness are common. If you struggle with these symptoms, do not stop taking your medication on your own; talk to your care team about symptom management, dose adjustments, or switching agents.
    • Tamoxifen: Often used for premenopausal women to block estrogen from reaching cancer cells [3].
    • Aromatase Inhibitors (AIs): Such as anastrozole, letrozole, or exemestane. These stop the body from making estrogen and are the standard for postmenopausal women [4].
    • Ovarian Function Suppression (OFS): For higher-risk premenopausal patients, doctors may use medications (like goserelin) or surgery to “shut down” the ovaries, often combined with an AI or tamoxifen [3].
  • Adjuvant CDK4/6 Inhibitors: If your cancer has features that suggest a higher risk of return (such as many involved lymph nodes or a large tumor size), your doctor may add a targeted drug to your hormone therapy for 2 to 3 years [5][6].
    • Abemaciclib (Verzenio): Used for 2 years specifically in defined high-risk, node-positive disease [5].
    • Ribociclib (Kisqali): Approved for a broader group of stage II and III patients who meet specific high-risk criteria, to be taken for 3 years, though criteria and approvals vary by country [6].

Metastatic Disease: First-Line Treatment

If the cancer is metastatic (Stage IV), the goal shifts to controlling the disease and maintaining your quality of life [7]. The standard first-line treatment for most patients is a combination of endocrine therapy and a CDK4/6 inhibitor [7], though this may not be appropriate in every situation, such as some cases of visceral crisis (rapid organ failure) or if the cancer progressed early on prior CDK4/6 therapy.

There are three main CDK4/6 inhibitors: palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio) [8]. They work by “braking” the cell cycle to stop cancer cells from dividing [8]. While they are highly effective, they require monitoring for side effects like low white blood cell counts (neutropenia), diarrhea, or changes in heart rhythm (QT prolongation), depending on the specific drug used [9][10].

Subsequent Treatments: Biomarker-Driven Care

If the cancer begins to grow again while on a CDK4/6 inhibitor, your doctor will likely perform a “liquid biopsy” (blood test) or a new tumor biopsy to look for specific genetic mutations that can guide the next choice [11][12].

  • ESR1 Mutations: If the cancer develops a mutation in the estrogen receptor gene, a drug called elacestrant (Orserdu)—the first oral SERD (Selective Estrogen Receptor Degrader)—may be used [11].
  • PIK3CA, AKT1, or PTEN Alterations: If these mutations are present, specific targeted drugs can be added to hormone therapy to bypass the resistance: alpelisib (Piqray) is specifically for PIK3CA-mutated disease, whereas capivasertib (Truqap) covers a different alteration set under its label including PIK3CA, AKT1, or PTEN [13][14]. These drugs require close monitoring for high blood sugar (hyperglycemia) and skin rashes [15][16].
  • BRCA1/2 Mutations: Patients with inherited BRCA mutations may be eligible for PARP inhibitors like olaparib or talazoparib, depending on setting and prior treatment [7][17].

The Role of Antibody-Drug Conjugates (ADCs)

Antibody-drug conjugates are a newer class of “smart” drugs that act like a homing missile, delivering chemotherapy directly to cells that have even a small amount of a specific protein on their surface [18].

  • Trastuzumab deruxtecan (Enhertu): This drug is a treatment option for patients with HER2-low or HER2-ultralow metastatic cancer, typically after they have tried endocrine therapies or chemotherapy, depending on current regulatory approvals [18][19]. It requires careful monitoring for a serious lung condition called interstitial lung disease (ILD) [P-144].
  • Sacituzumab govitecan (Trodelvy): This targets a protein called Trop-2 and is used in later lines of treatment for HR+/HER2- metastatic disease [20].
  • Datopotamab deruxtecan (Dato-DXd): Another Trop-2 targeting drug that has shown benefit for patients who have already received chemotherapy for metastatic disease [21].

These targeted therapies allow for a more personalized approach, ensuring you receive the right drug for the specific biology of your cancer at the right time [1].

Common questions in this guide

What is the usual treatment for early-stage HR-positive, HER2-negative breast cancer?
Treatment commonly starts with surgery, such as a lumpectomy or mastectomy, and may include radiation. Long-term endocrine therapy is the main systemic treatment and is often prescribed for 5 to 10 years. People with features that raise the risk of recurrence may also be offered an additional targeted medicine.
What medicines are commonly used for metastatic HR-positive, HER2-negative breast cancer?
For many people with metastatic disease, treatment begins with endocrine therapy plus a CDK4/6 inhibitor. The available inhibitors include palbociclib, ribociclib, and abemaciclib. The best choice depends on prior treatment, the pace and location of the cancer, other health conditions, and treatment goals.
How can biomarker testing change treatment after breast cancer progresses?
A blood test or new tumor biopsy can look for changes such as ESR1, PIK3CA, AKT1, or PTEN alterations, as well as inherited BRCA1 or BRCA2 mutations when appropriate. Results may identify targeted options, such as elacestrant, alpelisib, capivasertib, or a PARP inhibitor. Your oncologist will interpret the result in the context of your prior treatments and current disease.
What should I know about side effects from CDK4/6 inhibitors?
These medicines can lower white blood cell counts, cause diarrhea, or affect heart rhythm, depending on the drug. Monitoring may include blood tests and, for some medicines, an electrocardiogram. Report new or severe symptoms promptly so your care team can adjust treatment safely.
Can HER2-low or HER2-ultralow breast cancer be treated with Enhertu?
Some people with metastatic HR-positive, HER2-negative breast cancer whose tumors are HER2-low or HER2-ultralow may be candidates for trastuzumab deruxtecan, also called Enhertu. Eligibility depends on the exact test result, prior treatment, health status, and current regulatory approvals. This medicine requires monitoring for a serious lung problem called interstitial lung disease.
What are common side effects of long-term endocrine therapy?
Hot flashes, joint pain, and vaginal dryness are common with endocrine therapy, and some treatments can affect bone health. Do not stop the medicine on your own if side effects are difficult. Your care team can discuss symptom treatment, dose changes, switching medicines, and ways to monitor or protect bone health.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific clinicopathologic risk level, and does it qualify me for adjuvant CDK4/6 inhibitors like abemaciclib or ribociclib?
  2. 2.For my metastatic treatment, which CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is best suited for me, and what specific monitoring (like ECGs or blood tests) will I need?
  3. 3.If my cancer progresses, when and how will we test for mutations like ESR1, PIK3CA, or AKT1 to decide on the next targeted therapy?
  4. 4.Does my 'HER2-low' or 'HER2-ultralow' status make me a candidate for antibody-drug conjugates like Enhertu later in my treatment?
  5. 5.As a premenopausal patient, what are the pros and cons of ovarian function suppression compared to tamoxifen alone in my specific case?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

    Caswell-Jin JL, Somerfield MR, Khan MA, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026; 101200JCO2602034 doi:10.1200/JCO-26-02034.

    PMID: 42647767
  2. 2

    Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.

    Allison KH, Hammond MEH, Dowsett M, et al.

    Archives of pathology & laboratory medicine 2020; (144(5)):545-563 doi:10.5858/arpa.2019-0904-SA.

    PMID: 31928354
  3. 3

    Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.

    Burstein HJ, Lacchetti C, Anderson H, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(14)):1689-701 doi:10.1200/JCO.2015.65.9573.

    PMID: 26884586
  4. 4

    Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

    Burstein HJ, Lacchetti C, Anderson H, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(5)):423-438 doi:10.1200/JCO.18.01160.

    PMID: 30452337
  5. 5

    Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.

    Johnston SRD, Toi M, O'Shaughnessy J, et al.

    The Lancet. Oncology 2023; (24(1)):77-90 doi:10.1016/S1470-2045(22)00694-5.

    PMID: 36493792
  6. 6

    Ribociclib plus Endocrine Therapy in Early Breast Cancer.

    Slamon D, Lipatov O, Nowecki Z, et al.

    The New England journal of medicine 2024; (390(12)):1080-1091 doi:10.1056/NEJMoa2305488.

    PMID: 38507751
  7. 7

    Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.

    Burstein HJ, Somerfield MR, Barton DL, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(35)):3959-3977 doi:10.1200/JCO.21.01392.

    PMID: 34324367
  8. 8

    Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study.

    Provenzano L, Dieci MV, Curigliano G, et al.

    Annals of oncology : official journal of the European Society for Medical Oncology 2025; (36(7)):762-774 doi:10.1016/j.annonc.2025.03.023.

    PMID: 40204155
  9. 9

    Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm.

    Boyle F, Beith J, Burslem K, et al.

    Asia-Pacific journal of clinical oncology 2018; (14 Suppl 4()):3-11 doi:10.1111/ajco.13064.

    PMID: 30288930
  10. 10

    Hepatotoxicity across CDK 4/6 inhibitors: a Narrative Review.

    Wong WHF, Vasiliu S, McFarlane T

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2025; (33(7)):588 doi:10.1007/s00520-025-09625-0.

    PMID: 40524077
  11. 11

    Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

    Bidard FC, Kaklamani VG, Neven P, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(28)):3246-3256 doi:10.1200/JCO.22.00338.

    PMID: 35584336
  12. 12

    Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer.

    Zattarin E, Marra A, Palazzo A, et al.

    NPJ breast cancer 2025; (11(1)):145 doi:10.1038/s41523-025-00859-z.

    PMID: 41390667
  13. 13

    Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

    André F, Ciruelos E, Rubovszky G, et al.

    The New England journal of medicine 2019; (380(20)):1929-1940 doi:10.1056/NEJMoa1813904.

    PMID: 31091374
  14. 14

    Population Pharmacokinetics and Exposure-Response Analyses for Capivasertib in Combination With Fulvestrant in Patients With Breast Cancer.

    Fernandez Teruel C, Cullberg M, González-García I, et al.

    Clinical and translational science 2025; (18(7)):e70286 doi:10.1111/cts.70286.

    PMID: 40626336
  15. 15

    Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.

    Rugo HS, Lerebours F, Ciruelos E, et al.

    The Lancet. Oncology 2021; (22(4)):489-498 doi:10.1016/S1470-2045(21)00034-6.

    PMID: 33794206
  16. 16

    Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.

    Hu X, Zhang Q, Sun T, et al.

    Nature communications 2025; (16(1)):4324 doi:10.1038/s41467-025-59210-6.

    PMID: 40346047
  17. 17

    Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysis.

    Buonaiuto R, Fordellone M, Caltavituro A, et al.

    EClinicalMedicine 2025; (89()):103535 doi:10.1016/j.eclinm.2025.103535.

    PMID: 41079023
  18. 18

    Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.

    Bardia A, Hu X, Dent R, et al.

    The New England journal of medicine 2024; (391(22)):2110-2122 doi:10.1056/NEJMoa2407086.

    PMID: 39282896
  19. 19

    Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.

    Modi S, Jacot W, Yamashita T, et al.

    The New England journal of medicine 2022; (387(1)):9-20 doi:10.1056/NEJMoa2203690.

    PMID: 35665782
  20. 20

    Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.

    Rugo HS, Bardia A, Marmé F, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(29)):3365-3376 doi:10.1200/JCO.22.01002.

    PMID: 36027558
  21. 21

    Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.

    Bardia A, Jhaveri K, Im SA, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(3)):285-296 doi:10.1200/JCO.24.00920.

    PMID: 39265124

This page provides general information about HR-positive/HER2-negative breast cancer treatment and is not medical advice. Your oncology team can recommend medicines, testing, and monitoring based on your stage, biomarkers, health, and preferences.

Get notified when new evidence is published on Her2-receptor negative breast cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.